Abstract
Ceftaroline fosamil is a fairly new parenteral cephalosporin antibacterial approved by the US Food and Drug Administration (FDA) for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Drug-induced liver injury (DILI) is an important side effect profile to consider with antibiotic use. This case reports DILI in a previously healthy individual associated with a widely used antibiotic, ceftaroline, after only two doses. Discontinuation of the ceftaroline resulted in a resolution of DILI in a three-week period. Ceftaroline-induced liver injury is highlighted in this case report, along with a discussion of how we excluded other potential factors that can cause liver injury with the use of the Roussel Uclaf Causality Assessment Method (RUCAM) score. We also explained why other causes like hemochromatosis, Wilson's disease, celiac disease, and thyroid disease were unlikely.